Wegovy integration increases manufacturer dependence
Ro
Ro reduced one regulatory risk by moving from a gray zone supply model to an authorized drug channel, but in doing so it gave Novo Nordisk much more control over Ro's obesity economics. Once Wegovy started flowing through NovoCare in April 2025, Ro no longer had to rely as heavily on compounded semaglutide that was exposed to the end of shortage driven compounding. But price, supply access, and patient savings now depend more directly on Novo's channel rules, CenterWell fulfillment, and manufacturer funded promotions.
-
Compounded semaglutide had been attractive because Ro could wrap telehealth, prescribing, fulfillment, and follow up into one high margin flow. By 2024, GLP-1 revenue was about $370M for Ro, helped by monthly care fees, pharmacy economics, and high basket sizes. Brand integration protects access, but usually carries thinner spread economics than compounded supply.
-
The April 29, 2025 Novo expansion put Ro, Hims & Hers, and LifeMD into the same $499 cash pay Wegovy lane through NovoCare. That means sourcing is less of a moat. Competition shifts back to who can convert demand cheaper, keep patients on therapy longer, handle titration and side effects cleanly, and layer on enough service to justify subscription fees.
-
Manufacturer dependence is not theoretical. In June 2025, Novo ended direct Wegovy access for Hims & Hers while keeping Ro and LifeMD in the channel. That showed how quickly allocation and partnership decisions can reshape telehealth winners and losers when the drug maker controls the branded product and the promotional terms around it.
The next phase is a fight over who owns the patient relationship after drug access becomes standardized. Ro is pushing to be the care layer on top of manufacturer supply, with labs, dosing changes, insurance navigation, and long term monitoring. If it executes, Ro can keep obesity revenue durable even as branded GLP-1 pricing becomes more centralized and manufacturer controlled.